On Sunday, July 7, 2024, we exhibited at the Institute for Predictable Osseointegration in Implantology (IPOI), a non-profit organization (NPO) event held in Fukuoka City.
Read more
Mediplus Pharma, Inc. presented the safety and efficacy of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), in formulations for atopic dermatitis at the 123rd Annual Meeting of the Japanese Dermatological Association. The conference was held from June 6 to June 9, 2024, at the Kyoto International Conference Center.
For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000015.000079724.html
Mediplus Pharma, Inc. (CEO: Kenji Ito, HQ: Shibuya, Tokyo) presented on the multifunctionality and application of its proprietary ingredient, ozonized glycerin (Novel Glycerin Compound), as biomaterials at the 12th World Biomaterials Congress (WBC), held over six days from May 26 to 31, 2024, in Daegu, South Korea.
For more details on the press release, please visit here.
https://prtimes.jp/main/html/rd/p/000000013.000079724.html
We are pleased to announce our participation in the 16th Academic Conference of the Non-Profit Organization (NPO) Institute for Predictable Osseointegration in Implantology, which will be held on Sunday, July 7, 2024, in Fukuoka City.
We aim to introduce our unique ingredient , ozonized glycerin, which is expected to have beneficial effects in dental medicine, particularly in the surgical field. This event will be an opportunity for dental professionals, especially those active in the surgical domain, to learn about our product.
At our exhibition booth, attendees will be able to experience ozonized glycerin and deepen their understanding through explanations from the developers.
Mediplus Pharma Corporation (CEO: Kenji Ito, Headquarters: Shibuya, Tokyo) presented two academic papers about ozonized glycerin , a novel glycerin compound, at the international cosmetics researchers conference, IFSCC 2022 @ London (International Federation of Societies of Cosmetic Chemists Annual Congress, September 19-22, 2022).
Mediplus Pharma Inc. (Representative Director Kenji Ito, head office: Shibuya-ku, Tokyo) announces that the article on Mediplus Pharma’s patented ingredient: ozonized glycerin titled “Ozonized glycerin (OG)-based cosmetic products lighten age spots on human facial skin” was accepted into the American “Journal of Cosmetic Dermatology,” and used as the cover of the July 2022 issue of “Journal of Cosmetic Dermatology.”
Mediplus Pharma, Inc. (CEO: Kenji Ito, Head Office: Shibuya-ku, Tokyo,JAPAN) made a scientific presentation at the annual meeting of the Society for Investigative Dermatology (May 18-21, 2022, Portland, USA), which is considered the world’s highest-level society in dermatological research.